GO:0048715 negative regulation of oligodendrocyte differentiation: Molecular Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048715 describes any process that stops, prevents, or reduces the frequency, rate or extent of oligodendrocyte differentiation, the developmental transition of oligodendrocyte progenitor cells (OPCs) into mature myelin-forming oligodendrocytes.
• Galactosphingolipids such as sulfatide and galactocerebroside act as negative regulators of oligodendrocyte differentiation, and their loss in sulfatide-null mice accelerates differentiation in vivo.
• MicroRNAs, including miR-219 and miR-338, are central negative regulators that repress pro-differentiation transcripts and help time the onset of myelination.
• Cytoskeletal effectors such as non-muscle myosin II restrain oligodendrocyte morphological differentiation, showing that negative regulation operates at the level of process outgrowth and arborization.
• Extracellular matrix (ECM) proteins and their integrin receptors provide contextual negative and positive cues that modulate oligodendrocyte development and CNS myelination.
• Prolonged myelin deficits after ischaemic stroke contribute to neuron loss and functional impairment, underscoring why the brakes on oligodendrocyte differentiation must be precisely regulated.
Description
Oligodendrocyte differentiation is the developmental program by which oligodendrocyte progenitor cells (OPCs) exit the cell cycle, elaborate a complex arbor of processes, and ultimately ensheath axons with myelin in the central nervous system. This program must be tightly controlled in time and space, because premature or excessive differentiation depletes the OPC pool, whereas delayed differentiation leaves axons demyelinated and vulnerable. The Gene Ontology term GO:0048715, negative regulation of oligodendrocyte differentiation, captures the molecular and cellular processes that stop, prevent, or reduce the frequency, rate or extent of this differentiation program. Negative regulation of oligodendrocyte differentiation is not a single pathway but a convergence of multiple inhibitory inputs. These include lipid-based signals such as galactosphingolipids and sulfatide, microRNA-mediated repression of pro-differentiation transcripts, cytoskeletal brakes such as non-muscle myosin II, and extracellular matrix (ECM) cues that modulate integrin signaling. Transcription factors of the Id family have also been proposed as negative regulators, although genetic studies indicate that Id2 and Id4 are not the major negative regulators during early CNS development. For researchers, GO:0048715 matters because it defines the checkpoint that determines whether OPCs remain in a proliferative, repair-competent state or commit to myelination. Dysregulation of these brakes is implicated in myelin deficits after ischaemic stroke, in developmental myelination disorders, and in the failure of remyelination in chronic demyelinating disease. Understanding which genes enforce negative regulation, and how, is therefore essential for designing strategies to promote repair without exhausting the progenitor pool.
negative regulation of oligodendrocyte differentiation At A Glance
| GO ID | GO:0048715 |
|---|---|
| GO term | negative regulation of oligodendrocyte differentiation |
| Ontology | biological_process |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of oligodendrocyte differentiation. |
| Synonyms | down regulation of oligodendrocyte differentiation; down-regulation of oligodendrocyte differentiation; downregulation of oligodendrocyte differentiation; inhibition of oligodendrocyte differentiation |
| Major function | Restrains the timing and extent of OPC-to-oligodendrocyte transition, preserving the progenitor pool and preventing premature myelination |
| Key molecular classes | Galactosphingolipids and sulfatide; microRNAs such as miR-219/miR-338; non-muscle myosin II; ECM proteins and integrins |
| Related process | Positive regulation of oligodendrocyte differentiation; OPC proliferation; CNS myelination |
| Disease relevance | Myelin deficits after ischaemic stroke; demyelinating and remyelination failure states |
What Is GO:0048715?
GO:0048715, negative regulation of oligodendrocyte differentiation, is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of oligodendrocyte differentiation. In practical terms, it covers every molecular mechanism that restrains an OPC from becoming a mature, myelin-forming oligodendrocyte, including inhibitory extracellular signals, intracellular signaling cascades, microRNA-mediated repression, and cytoskeletal constraints.
Why Is negative regulation of oligodendrocyte differentiation Important in Cell Biology?
Negative regulation of oligodendrocyte differentiation is important because it sets the threshold and timing for myelination in the central nervous system. Without inhibitory control, OPCs would differentiate prematurely, depleting the progenitor pool needed for developmental myelination and adult remyelination. Conversely, excessive or prolonged negative regulation leaves axons unmyelinated, and prolonged myelin deficits after ischaemic stroke contribute to neuron loss and functional impairments. The term therefore sits at the intersection of developmental neurobiology, myelin repair, and neurological disease, and it provides a framework for identifying druggable brakes that could be released to promote remyelination.
• Defines the checkpoint that controls when OPCs exit the cell cycle and commit to myelination.
• Preserves the OPC pool by preventing premature differentiation during CNS development.
• Galactosphingolipids and sulfatide act as negative regulators, and their loss accelerates differentiation in vivo.
• MicroRNA-mediated repression, including miR-219 and miR-338, times the onset of oligodendrocyte differentiation.
• Cytoskeletal brakes such as non-muscle myosin II restrain morphological differentiation and process outgrowth.
• ECM proteins and integrin signaling provide contextual negative and positive cues for myelination.
• Prolonged myelin deficits after ischaemic stroke contribute to neuron loss and functional impairment.
• Id2 and Id4 are not the major negative regulators during early CNS development, highlighting the need for rigorous genetic validation.
• Provides candidate targets for promoting remyelination in demyelinating disease.
• Offers a conceptual framework for interpreting transcriptomic and genetic screens of oligodendrocyte development.
What Happens During negative regulation of oligodendrocyte differentiation?
Inhibitory lipid and galactosphingolipid signals
In simple terms: Certain fat-like molecules on the surface of oligodendrocyte precursors act as brakes that keep the cells from maturing too early.
Galactosphingolipids, including galactocerebroside and its sulfated derivative sulfatide, are enriched in myelin and on the surface of differentiating oligodendrocytes. In culture, galactosphingolipids negatively regulate oligodendrocyte differentiation, and sulfatide-null mice show accelerated differentiation in vivo, demonstrating that these lipids act as a brake on the differentiation program. This lipid-based negative regulation is one of the best-characterized mechanisms under GO:0048715 and provides a direct link between myelin lipid composition and the timing of differentiation.
MicroRNA-mediated repression of pro-differentiation transcripts
In simple terms: Small RNA molecules act as silencers that reduce the production of proteins that would otherwise push the cell to mature.
MicroRNAs provide a post-transcriptional layer of negative regulation. miR-219 and miR-338 are induced during oligodendrocyte differentiation and repress transcripts that inhibit differentiation, thereby acting as negative regulators of the differentiation program. This microRNA-mediated control is essential for proper timing of oligodendrocyte differentiation and myelination, and it illustrates how GO:0048715 can be enforced by small non-coding RNAs rather than by proteins alone.
Cytoskeletal restraint of morphological differentiation
In simple terms: The cell's internal skeleton can act as a brake that prevents the precursor from growing the long branches needed to wrap axons.
Morphological differentiation of oligodendrocytes requires extensive process outgrowth and arborization. Non-muscle myosin II is a negative regulator of oligodendrocyte morphological differentiation, and its inhibition promotes process formation. This shows that GO:0048715 includes cytoskeletal mechanisms that restrain the shape changes required for myelination, in addition to transcriptional and signaling brakes.
Extracellular matrix and integrin-dependent contextual cues
In simple terms: The material surrounding the cell sends stop-and-go signals that help decide whether the cell should mature.
ECM proteins and their integrin receptors modulate oligodendrocyte development and CNS myelination, providing contextual negative and positive cues. Depending on the ECM composition and the integrin repertoire, signaling can restrain or promote differentiation, and this contextual regulation is an important component of GO:0048715. ECM-based negative regulation helps ensure that differentiation occurs only in a permissive microenvironment.
Transcription factor control and the Id family
In simple terms: Some transcription factors were thought to be the main brakes, but genetic tests showed they are not the major ones early in development.
Transcription factors such as Id2 and Id4 have been proposed as negative regulators of oligodendrocyte differentiation. However, genetic analysis in mice demonstrated that Id2 and Id4 are not the major negative regulators during early CNS development, indicating that redundant or alternative mechanisms enforce GO:0048715. This finding is a caution against assuming that any inhibitor identified in vitro is a dominant negative regulator in vivo.
Integration of negative regulation with myelin repair
In simple terms: After injury, the same brakes that control normal development can slow down myelin repair.
Negative regulation of oligodendrocyte differentiation is not limited to development; it also influences remyelination after injury. Prolonged myelin deficits after ischaemic stroke contribute to neuron loss and functional impairments, indicating that failure to overcome negative regulation or to sustain differentiation has lasting consequences. Understanding how the brakes are applied and released is therefore central to promoting repair.
Key Genes Involved in GO:0048715 negative regulation of oligodendrocyte differentiation
The following genes and gene products have been experimentally implicated in negative regulation of oligodendrocyte differentiation or in the closely related control of oligodendrocyte development and CNS myelination.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALC | Galactosylceramidase; regulates galactosphingolipid levels including galactocerebroside and sulfatide | Loss-of-function alters lipid-mediated negative regulation of oligodendrocyte differentiation |
| UGT8 | UDP-galactose ceramide galactosyltransferase; synthesizes galactocerebroside, a precursor of sulfatide | Key enzyme for galactosphingolipid-based negative regulation |
| CST | Galactocerebroside sulfotransferase; produces sulfatide | Sulfatide is a negative regulator of oligodendrocyte differentiation |
| MIR219A | MicroRNA that represses pro-differentiation transcripts | Central microRNA-mediated negative regulation of oligodendrocyte differentiation |
| MIR338 | MicroRNA that represses transcripts inhibitory to differentiation | Coordinates timing of oligodendrocyte differentiation and myelination |
| MYH9 | Non-muscle myosin II heavy chain; restrains morphological differentiation | Inhibition promotes process outgrowth in oligodendrocytes |
| MYH10 | Non-muscle myosin II heavy chain; cytoskeletal brake | Contributes to negative regulation of oligodendrocyte morphological differentiation |
| ID2 | Helix-loop-helix transcription factor proposed as a negative regulator | Genetic studies show it is not the major negative regulator during early CNS development |
| ID4 | Helix-loop-helix transcription factor proposed as a negative regulator | Genetic studies show it is not the major negative regulator during early CNS development |
| ITGB1 | Integrin beta 1; mediates ECM-dependent signaling | Modulates oligodendrocyte development and CNS myelination |
| ITGAV | Integrin alpha V; ECM receptor | Contributes to ECM-dependent regulation of oligodendrocyte development |
| LAMA2 | Laminin subunit alpha 2; ECM protein | ECM protein that modulates oligodendrocyte development and myelination |
| LAMB1 | Laminin subunit beta 1; ECM protein | ECM protein implicated in CNS myelination control |
| FN1 | Fibronectin; ECM protein | ECM cue that influences oligodendrocyte differentiation |
| TNR | Tenascin R; ECM protein | ECM protein that modulates oligodendrocyte development |
| CNTN1 | Contactin 1; cell adhesion molecule | Cell adhesion molecule involved in myelination-related signaling |
| PLP1 | Proteolipid protein 1; major myelin protein | Marker of mature oligodendrocytes; its expression marks the endpoint of differentiation |
| MBP | Myelin basic protein; major myelin protein | Marker of mature oligodendrocytes used to assess differentiation state |
How Is negative regulation of oligodendrocyte differentiation Regulated?
Negative regulation of oligodendrocyte differentiation is itself regulated at multiple levels. Galactosphingolipid and sulfatide levels are controlled by biosynthetic enzymes such as UGT8 and CST and by the degradative enzyme GALC, so changes in lipid metabolism shift the balance between progenitor maintenance and differentiation. MicroRNAs such as miR-219 and miR-338 are induced during differentiation and repress transcripts that would otherwise inhibit the program, creating a feed-forward loop that times differentiation onset. Cytoskeletal regulators such as non-muscle myosin II are modulated by signaling pathways that control process outgrowth, so the cytoskeletal brake can be released when differentiation is appropriate. ECM composition and integrin expression provide an additional layer of contextual regulation, allowing the microenvironment to tune the strength of negative regulation. Finally, transcription factor networks contribute to the regulation, although genetic evidence indicates that Id2 and Id4 are not the dominant negative regulators during early CNS development.
negative regulation of oligodendrocyte differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALC | Galactosphingolipid metabolism; altered negative regulation of oligodendrocyte differentiation | Galc knockout or point-mutation models with lipid profiling and differentiation assays |
| UGT8 | Galactocerebroside and sulfatide synthesis; developmental myelination | Ugt8 knockout models to test loss of lipid-based negative regulation |
| CST | Sulfatide production; negative regulation of oligodendrocyte differentiation | Cst knockout or knockdown to assess accelerated differentiation |
| MIR219A | MicroRNA-mediated control of oligodendrocyte differentiation and myelination | miR-219 knockout or overexpression models with transcriptomic readouts |
| MYH9 | Cytoskeletal restraint of oligodendrocyte morphological differentiation | Myh9 knockout or point-mutation models with morphometric analysis |
| ITGB1 | ECM-dependent modulation of oligodendrocyte development and myelination | Conditional Itgb1 knockout in oligodendrocyte lineage cells |
Ischaemic stroke and prolonged myelin deficits
After ischaemic stroke, prolonged myelin deficits contribute to neuron loss and functional impairments, indicating that failure to restore oligodendrocyte differentiation and myelination has lasting consequences for brain function. Negative regulation of oligodendrocyte differentiation is relevant because persistent brakes on differentiation can prevent OPCs from maturing into myelin-forming cells during the repair window.
Demyelinating disease and remyelination failure
In chronic demyelinating conditions, remyelination failure is often attributed to impaired OPC differentiation rather than to a lack of progenitors. Mechanisms that enforce GO:0048715, including lipid-based inhibition by galactosphingolipids and sulfatide, microRNA-mediated repression, and cytoskeletal restraint by non-muscle myosin II, are candidate contributors to this differentiation block. ECM proteins and integrin signaling further modulate whether the lesion microenvironment permits differentiation.
Developmental myelination disorders
Because negative regulation of oligodendrocyte differentiation times the onset of myelination, perturbations in its components can alter developmental myelination. Sulfatide-null mice show accelerated differentiation, demonstrating that loss of a negative regulator changes the developmental trajectory in vivo. MicroRNA-mediated control is also required for proper timing of differentiation and myelination, so disruption of these pathways can produce developmental myelin abnormalities.
Genetic architecture of brain connectivity
Genetic variation influencing the structural connectome includes genes related to oligodendrocyte biology and myelination, linking the molecular control of oligodendrocyte differentiation to individual differences in brain wiring. This connection suggests that negative regulation of oligodendrocyte differentiation may contribute to the genetic architecture of white matter structure and connectivity.
From negative regulation of oligodendrocyte differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required to restrain oligodendrocyte differentiation in vivo? | Knockout model in the oligodendrocyte lineage with differentiation and myelin markers |
| Does a specific residue or domain mediate the inhibitory function? | Point-mutation knock-in of the candidate gene |
| Does the candidate gene product need to be tagged for localization studies? | Tagged knock-in (e.g., fluorescent or epitope tag) |
| Does overexpression of the candidate gene delay differentiation? | Overexpression model using viral or transgenic delivery |
| Does loss of a microRNA accelerate differentiation? | miR-219 or miR-338 knockout and overexpression models |
| Does ECM composition change the strength of negative regulation? | ECM-coated culture models with integrin loss-of-function |
How to Study the negative regulation of oligodendrocyte differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA sequencing | Transcriptome changes during differentiation | Discovering candidate negative regulators and validating microRNA targets |
| MicroRNA mimic/inhibitor assays | Effect of a microRNA on differentiation | Testing miR-219 and miR-338 function |
| Luciferase reporter assay | Direct microRNA-target interaction | Validating repression of pro-differentiation transcripts |
| Immunofluorescence imaging | Process outgrowth and differentiation markers | Assessing morphological differentiation and myosin II effects |
| Lipidomics | Galactocerebroside and sulfatide levels | Linking lipid composition to negative regulation |
| Western blotting | Protein levels of myelin and differentiation markers | Confirming differentiation state across genotypes |
| Electron microscopy | Myelin ultrastructure and ensheathment | Evaluating myelination in vivo |
| Behavioral testing | Functional consequences of myelin deficits | Assessing outcomes after ischaemic stroke models |
Transcriptomic profiling of differentiation states
RNA sequencing of OPCs, differentiating oligodendrocytes, and mature oligodendrocytes can identify transcripts whose expression changes as cells exit the progenitor state and commit to differentiation. This approach is useful for discovering candidate negative regulators and for validating microRNA targets such as those controlled by miR-219 and miR-338. Comparing wild-type and mutant cells, for example sulfatide-null or Galc-mutant cells, can reveal how loss of a negative regulator reshapes the differentiation transcriptome.
MicroRNA target and function analysis
Because microRNAs are central to negative regulation of oligodendrocyte differentiation, methods such as target prediction combined with luciferase reporter assays, Argonaute immunoprecipitation, and microRNA mimic/inhibitor experiments are used to establish direct repression. These approaches help distinguish microRNA-mediated negative regulation from indirect effects on differentiation.
Morphological and cytoskeletal imaging
Immunofluorescence and live-cell imaging of process outgrowth, arborization, and myelin-like membrane formation allow direct assessment of morphological differentiation. Such imaging is particularly informative for cytoskeletal regulators such as non-muscle myosin II, whose inhibition promotes process formation. Combining imaging with markers such as MBP and PLP1 provides a readout of differentiation state.
Lipid profiling and myelin biochemistry
Because galactosphingolipids and sulfatide act as negative regulators, lipidomic and biochemical methods that quantify galactocerebroside and sulfatide are essential for linking lipid composition to differentiation state. These methods are typically combined with genetic loss-of-function models to test causality.
How CRISPR Can Be Used to Study GO:0048715 negative regulation of oligodendrocyte differentiation
Knockout
CRISPR knockout of candidate negative regulators such as Galc, Ugt8, Cst, Mir219a, or Myh9 allows direct testing of whether loss of the gene accelerates oligodendrocyte differentiation. For example, sulfatide-null mice show accelerated differentiation, so CRISPR knockout of Cst or Ugt8 in cell models can reproduce and dissect this phenotype. Knockout of microRNA genes can similarly test whether miR-219 or miR-338 is required to restrain differentiation.
Point Mutation
Point-mutation knock-in can be used to test whether specific residues or domains are required for the inhibitory function of a negative regulator. For cytoskeletal regulators such as non-muscle myosin II, point mutations that impair motor activity or regulation can separate effects on process outgrowth from effects on other functions. Point mutations in lipid-metabolizing enzymes can also reveal which catalytic activities are required for negative regulation.
Knock-in
Knock-in of tags or reporters into endogenous loci enables tracking of negative regulator expression and localization during differentiation. Tagged knock-in of ECM proteins or integrins can reveal where and when these cues act during oligodendrocyte development. Reporter knock-in of differentiation markers such as MBP or PLP1 provides a live readout of differentiation state.
Overexpression
CRISPR-based overexpression or viral overexpression of a candidate negative regulator can test whether increased dosage delays differentiation. Overexpression of miR-219 or miR-338, for example, is expected to repress pro-differentiation transcripts and delay differentiation. Overexpression of ECM proteins or integrins can similarly test whether specific microenvironmental cues strengthen negative regulation.
How EDITGENE Supports negative regulation of oligodendrocyte differentiation Research
Researchers studying negative regulation of oligodendrocyte differentiation-related genes often need to determine whether a candidate gene is causally involved in restraining OPC differentiation or is merely correlated with the differentiation state. Establishing causality requires precise genetic models in which the candidate gene can be deleted, mutated, tagged, or overexpressed in the oligodendrocyte lineage, followed by quantitative readouts of differentiation and myelination.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of oligodendrocyte differentiation research.
Frequently Asked Questions About negative regulation of oligodendrocyte differentiation
What is negative regulation of oligodendrocyte differentiation (GO:0048715)?
GO:0048715 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of oligodendrocyte differentiation, the developmental transition of OPCs into mature myelin-forming oligodendrocytes.
What genes are involved in negative regulation of oligodendrocyte differentiation?
Genes and gene products implicated include galactosphingolipid and sulfatide pathway enzymes such as GALC, UGT8, and CST, microRNAs such as miR-219 and miR-338, cytoskeletal regulators such as non-muscle myosin II, and ECM-related genes such as integrins and laminins.
How do galactosphingolipids negatively regulate oligodendrocyte differentiation?
Galactosphingolipids, including galactocerebroside and sulfatide, act as negative regulators of oligodendrocyte differentiation, and sulfatide-null mice show accelerated differentiation in vivo.
Do microRNAs control oligodendrocyte differentiation?
Yes. miR-219 and miR-338 are induced during differentiation and repress transcripts that would otherwise inhibit the program, providing microRNA-mediated negative regulation.
Is non-muscle myosin II a negative regulator of oligodendrocyte differentiation?
Yes. Non-muscle myosin II acts as a negative regulator of oligodendrocyte morphological differentiation, and its inhibition promotes process outgrowth.
Are Id2 and Id4 major negative regulators of oligodendrocyte differentiation?
Genetic studies indicate that Id2 and Id4 are not the major negative regulators of oligodendrocyte differentiation during early central nervous system development.
How does negative regulation of oligodendrocyte differentiation relate to myelin repair?
Persistent negative regulation can prevent OPCs from maturing into myelin-forming cells, and prolonged myelin deficits after ischaemic stroke contribute to neuron loss and functional impairments.
What experimental models are used to study GO:0048715?
Common models include knockout, point-mutation, knock-in, and overexpression cell and animal models, combined with transcriptomic, imaging, and lipid profiling readouts.
What methods measure negative regulation of oligodendrocyte differentiation?
RNA sequencing, microRNA mimic and inhibitor assays, luciferase reporters, immunofluorescence imaging, lipidomics, and western blotting are commonly used.
Why is negative regulation of oligodendrocyte differentiation important for disease?
Dysregulation of these brakes is linked to myelin deficits after ischaemic stroke, remyelination failure in demyelinating disease, and developmental myelination abnormalities.
Conclusion
GO:0048715, negative regulation of oligodendrocyte differentiation, defines the molecular brakes that time and limit the transition of OPCs into mature myelin-forming oligodendrocytes. These brakes include lipid-based signals such as galactosphingolipids and sulfatide, microRNA-mediated repression, cytoskeletal restraint by non-muscle myosin II, and ECM-dependent contextual cues. Genetic studies also caution that not all proposed inhibitors, such as Id2 and Id4, are dominant negative regulators in vivo. Because prolonged myelin deficits after ischaemic stroke contribute to neuron loss and functional impairment, understanding how to modulate these brakes is a major goal for myelin repair research. Precise CRISPR models, combined with transcriptomic, imaging, and lipid profiling methods, provide the tools needed to identify causal negative regulators and to test whether releasing them can promote remyelination.
References
- 1. Cheng YJ et al.. 2024. Prolonged myelin deficits contribute to neuron loss and functional impairments after ischaemic stroke.. Brain 147(4):1294-1311 PMID: 38289861
- 2. Yamada M et al.. 2022. The molecular regulation of oligodendrocyte development and CNS myelination by ECM proteins.. Front Cell Dev Biol 10:952135 PMID: 36147746
- 3. Bansal R et al.. 1999. Negative regulation of oligodendrocyte differentiation by galactosphingolipids.. J Neurosci 19(18):7913-24 PMID: 10479693
- 4. Zhao X et al.. 2010. MicroRNA-mediated control of oligodendrocyte differentiation.. Neuron 65(5):612-26 PMID: 20223198
- 5. Wainberg M et al.. 2024. Genetic architecture of the structural connectome.. Nat Commun 15(1):1962 PMID: 38438384
- 6. Wang H et al.. 2012. Myosin II is a negative regulator of oligodendrocyte morphological differentiation.. J Neurosci Res 90(8):1547-56 PMID: 22437915
- 7. Huang H et al.. 2022. Id2 and Id4 are not the major negative regulators of oligodendrocyte differentiation during early central nervous system development.. Glia 70(3):590-601 PMID: 34889481
- 8. Hirahara Y et al.. 2004. Sulfatide is a negative regulator of oligodendrocyte differentiation: development in sulfatide-null mice.. Glia 45(3):269-77 PMID: 14730700
